Cromos Pharma, where the patients are

UCB

UCB, Sanofi partner for immune-mediated diseases innovation

Wednesday, March 12, 2014 01:47 PM

UCB, a global biopharmaceutical company focused on the discovery and development of medicines for the immune system and central nervous system, and Sanofi, an integrated global healthcare provider, have entered a scientific and strategic collaboration for the discovery and development of innovative anti-inflammatory small molecules, which have the potential to treat immune-mediated diseases in areas such as gastroenterology and arthritis.

More... »

CRF Health eCOA webinar series

UCB announces CEO succession plan

Monday, February 24, 2014 12:09 PM

UCB, a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions for the immune system and of the central nervous system, and CEO Roch Doliveux have announced the implementation of its CEO succession plan.

More... »


Amgen, UCB release positive phase II data for romosozumab

Tuesday, January 7, 2014 09:00 AM

Amgen and UCB have announced results from a phase II trial evaluating romosozumab (AMG 785/CDP7851) in postmenopausal women with low bone mineral density (BMD). Published in the New England Journal of Medicine (NEJM), the trial demonstrated that, compared with placebo, romosozumab treatment for 12 months significantly increased BMD at the lumbar spine, total hip and femoral neck. Significant increases also were observed in the first BMD assessment at three months. Moreover, in exploratory analyses, increases observed at the lumbar spine and hip were significantly greater than those observed with current treatments FOSAMAX (alendronate sodium) and FORTEO/FORSTEO (teriparatide).

More... »

Aeterna Zentaris appoints Richard Sachse chief scientific officer

Friday, January 3, 2014 09:51 AM

Aeterna Zentaris, a specialty biopharmaceutical company, has appointed Richard Sachse, M.D., Ph.D., senior vice president, chief scientific officer. Before joining Aeterna Zentaris, Sachse was vice president, head of Global Translational Medicine at Boehringer Ingelheim.

More... »

Oncodesign, UCB collaborate on neurodegenerative diseases

Thursday, November 14, 2013 10:00 AM

Oncodesign, a drug discovery company and oncology pharmacology service provider, has entered into a research collaboration and exclusive license option with UCB, a global biopharmaceutical provider specialized in neurology and immunology. The collaboration will bring innovative therapeutic solutions to patients suffering from neurodegenerative disorders. Oncodesign will apply its Nanocyclix technology on a kinase target selected by UCB, with the aim of discovering potent and selective inhibitors that cross the blood brain barrier.

More... »

PPD names VP for global product development

Monday, September 23, 2013 01:30 PM

CRO PPD has appointed Gregory Dennis, M.D., vice president of global product development. Dennis will be therapeutic area head, providing medical and scientific expertise for rheumatology, immunology and inflammatory diseases.

More... »

UCB, IBM collaborate to personalize care for epilepsy patients

Wednesday, May 22, 2013 11:05 AM

UCB, a Belgium-based global biopharmaceutical company focused on diseases of the immune system and central nervous system, and IBM have completed the initial phase of a project designed to harness the power of analytics to help healthcare providers deliver more highly personalized care to people living with epilepsy. The milestone marks the critical first step in the path towards eventually harnessing the transformative power of cognitive computing capabilities, such as IBM Watson, for epilepsy care.

More... »

UCB and ConfometRx announce new R&D partnership

Friday, February 22, 2013 12:13 PM

UCB, a Belgium-based biopharmaceutical company, has sealed a research agreement with Santa Clara, Calif.-based ConfometRx to enable the discovery of novel medicines addressing unmet medical needs in neuroscience.

More... »

$262M Pan-European drug discovery platform launched

Friday, February 8, 2013 10:48 AM

The European Lead Factory, a novel platform for innovative drug discovery, was launched Feb. 7 by an international consortium of 30 partners. The partnership, the first of its kind, is supported by the Innovative Medicines Initiative (IMI) and creates opportunities for the discovery of new medicines by providing public partners with an “industry-like” discovery platform to translate cutting-edge academic research into high-quality drug lead molecules on a scale and speed that was not possible previously.

More... »

Aesica wins European Outsourcing award for UCB acquisition strategy

Thursday, November 1, 2012 10:53 AM

Aesica, a global contract manufacturing organization, has won the European Outsourcing award for ‘best acquisition’ following the successful acquisition and integration of three different UCB sites—at Monheim and Zwickau, Germany, and Pianezza in, Italy, in 2011.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs